SAGE Therapeutics downgraded by RBC Capital Mkts with a new price target
$SAGE
Biotechnology: Pharmaceutical Preparations
Health Care
RBC Capital Mkts downgraded SAGE Therapeutics from Outperform to Sector Perform and set a new price target of $4.00 from $10.00 previously